Is Eculizumab a targeted drug?

Eculizumab (Eculizumab) is a targeted drug. It is a monoclonal antibody that targets complement protein C5. It can prevent the cleavage into C5a and C5b and form the terminal complement complex C5. b-9, inhibition of this complex prevents complement-mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria, complement-mediated microangiopathy in atypical hemolytic uremic syndrome, and immune-mediated inflammation and central nervous system damage in neuromyelitis optica spectrum disorder.

Eculizumab (Eculizumab) is suitable for the treatment of patients with paroxysmal nocturnal hemoglobinuria to reduce hemolysis; it is also suitable for the treatment of patients with atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy; it is also suitable for the treatment of generalized myasthenia gravis in adults with anti-acetylcholine receptor (AchR) antibody-positive; and it is also suitable for the treatment of anti-aquaporin-4 (AQ) P4) Neuromyelitis optica spectrum disorder in antibody-positive adult patients. One use limitation of eculizumab is that it is not indicated for the treatment of patients with Shiga toxin E. coli-associated hemolytic uremic syndrome (STEC-HUS).

The generic drug Eculizumab has been launched in China and is covered by medical insurance. It is only available for reimbursement to eligible patients. The specification is 300mg (30ml) and the price per box may be more than 3,000 yuan. It is understood that the price of each box of the original Eculizumab drug sold overseas is more than 6,000 US dollars (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold at home and abroad are basically the same, and the price of the original drug is still relatively expensive. There are currently no generic versions of eculizumab available on the market.